Concepedia

Publication | Open Access

A phase I clinical trial demonstrates that nfP2X<sub>7</sub>-targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma

DOIFull Paper Access

96

Citations

25

References

2017

Year

S.M. Gilbert, Amy Baird, S Glazer, Julian A. Barden, Andrew M. Glazer, Liew Cheng Teh, Jennifer King
British Journal of Dermatology

Abstract

Antibodies against nfP2X<sub>7</sub> (BIL010t) provide a novel, safe and well-tolerated treatment for BCC.

References

YearCitations

Page 1